ARCHIVES

“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s

This article is from The Cancer Letter archive.

Vol. 17 No. 36 | September 20, 1991

Download PDF Visit The Full Archive

Related Articles

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013

NIH Director Varmus Names President of Sloan-Kettering, Succeeding Mark

October 15, 1999

NCI Cooperative Group, Cancer Center Trials Listed

January 30, 2009

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

NCI To Broaden Support, Especially For Staff, Through Core Grants to Comprehensive Centers

November 21, 1975

NCI Director Sets A Goal: Eliminate Suffering, Death From Cancer By 2015

February 14, 2003